We use technically necessary cookies for the operation of the website. Other cookies are only set with your consent. We use these to statistically analyse the use of the website (location, time, end device, referrer URL). We also share information about the use of the website with our provider Google LLC. We have also integrated videos into our website via the provider Vimeo, a video hosting platform. The service provider is Vimeo Inc. Both providers may combine this information with other data. Your data may also be transferred to the USA. The USA (and other non-EEA countries) do not offer a level of data protection comparable to the EU; for example, government agencies can access data without any reason. However, both Google LLC. and Vimeo Inc. are committed to data protection-compliant processing with the EU standard contractual clauses.
You can revoke your consent to cookies and data transfer at any time with effect for the future. You can find more information in our privacy policy.

These cookies help making a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.

These cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously. With this information we can constantly improve the experience we offer on our website.

These cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.

  • Home
  • About medac
  • Information for patients
  • Healthcare professionals
  • Products
  • Career opportunities
  • Media
  • Dealing with the COVID-19 pandemic

    Guideline for cancer patients

    New and unique
    SARS-CoV-2 surrogate neutralisation test

    For the first time, with the cPass test, there is now a method available to anyone to test the blocking effect of neutralising COVID-19 antibodies.

    Find out more

    To our job offers

    No matter whether you are looking for an internship, a job as a university graduate or you want to take the next step in your career as an applicant with work experience: You can find the whole spectrum on the following pages.

    Find our more


    Our expertise as a pharmaceutical company

    medac is a future-oriented company and has been growing dynamically since fifty years. More than 2000 medac employees work on the first-time development and further refinement of pharmaceuticals and medical products for the diagnosis and treatment of oncological, urological and auto-immune diseases. Especially when it is a question of niche products we are one of the leading pharmaceutical companies. We represent solid values and basically think in human terms. This results in long-lasting business partnership relations with clinics, doctors and laboratories, as well as providing a healthy working atmosphere for all our employees




    A reliable diagnosis with the new cPass test by medac GmbH

    Is it possible that I’m already immune to COVID-19?

    In the time of lockdowns and vaccination chaos, a new diagnostic procedure finally provides...

    medac statement on Coronavirus (SARS-CoV-2)

    At this moment in time, and after consultation of the competent authorities, we do not foresee any interruptions in production and therefore no supply...

    Trecondi® - the new original from medac

    After 20 years of intensive research and development activity in the field of haematology and oncology, medac received EU-wide marketing authorisation...

    Delivery failure urokinase

    Urokinase medac is not available at the moment. At present, work is underway on a new production of the drug in order to provide patients with...

    medac at the EBMT 2019

    Innovative conditioning therapy for MDS and AML

    Warning of the off-label use of BCG-medac for the prevention (vaccination) or treatment of COVID-19

    The experimental use of BCG-medac as a vaccine against COVID-19 is associated with a high risk of serious adverse reactions and should therefore be strictly avoided. The Federal Institute for Vaccines and Biomedical Medicines (Paul-Ehrlich Institut (PEI)) has published a respective safety information:


    No news available.
    Nach oben